These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21816030)

  • 1. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.
    Lievens M; Aponte JJ; Williamson J; Mmbando B; Mohamed A; Bejon P; Leach A
    Malar J; 2011 Aug; 10():222. PubMed ID: 21816030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
    Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR;
    Malar J; 2011 Aug; 10():224. PubMed ID: 21816029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
    RTS,S Clinical Trials Partnership
    Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
    Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
    Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
    Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
    PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease.
    Penny MA; Pemberton-Ross P; Smith TA
    Malar J; 2015 Nov; 14():437. PubMed ID: 26537608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
    ; Agnandji ST; Lell B; Soulanoudjingar SS; Fernandes JF; Abossolo BP; Conzelmann C; Methogo BG; Doucka Y; Flamen A; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Nhamuave A; Quelhas D; Bassat Q; Mandjate S; Macete E; Alonso P; Abdulla S; Salim N; Juma O; Shomari M; Shubis K; Machera F; Hamad AS; Minja R; Mtoro A; Sykes A; Ahmed S; Urassa AM; Ali AM; Mwangoka G; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Tahita MC; Kaboré W; Ouédraogo S; Sandrine Y; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Odero C; Oneko M; Otieno K; Awino N; Omoto J; Williamson J; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Nekoye O; Gondi S; Otieno A; Ogutu B; Wasuna R; Owira V; Jones D; Onyango AA; Njuguna P; Chilengi R; Akoo P; Kerubo C; Gitaka J; Maingi C; Lang T; Olotu A; Tsofa B; Bejon P; Peshu N; Marsh K; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Ayamba S; Kayan K; Owusu-Ofori R; Dosoo D; Asante I; Adjei G; Adjei G; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Kilavo H; Mahende C; Liheluka E; Lemnge M; Theander T; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Agyekum A; Owusu L; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Msika A; Jumbe A; Chome N; Nyakuipa D; Chintedza J; Ballou WR; Bruls M; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Vekemans J; Carter T; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
    N Engl J Med; 2011 Nov; 365(20):1863-75. PubMed ID: 22007715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
    Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Advanced Development Pathway of the RTS,S/AS01 Vaccine.
    von Seidlein L
    Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.
    Bejon P; White MT; Olotu A; Bojang K; Lusingu JP; Salim N; Otsyula NN; Agnandji ST; Asante KP; Owusu-Agyei S; Abdulla S; Ghani AC
    Lancet Infect Dis; 2013 Apr; 13(4):319-27. PubMed ID: 23454164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
    Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
    PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
    Agnandji ST; Fernandes JF; Bache EB; Ramharter M
    Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
    Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
    Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.
    Ockenhouse CF; Regules J; Tosh D; Cowden J; Kathcart A; Cummings J; Paolino K; Moon J; Komisar J; Kamau E; Oliver T; Chhoeu A; Murphy J; Lyke K; Laurens M; Birkett A; Lee C; Weltzin R; Wille-Reece U; Sedegah M; Hendriks J; Versteege I; Pau MG; Sadoff J; Vanloubbeeck Y; Lievens M; Heerwegh D; Moris P; Guerra Mendoza Y; Jongert E; Cohen J; Voss G; Ballou WR; Vekemans J
    PLoS One; 2015; 10(7):e0131571. PubMed ID: 26148007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
    Vandoolaeghe P; Schuerman L
    Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
    Vandoolaeghe P; Schuerman L
    Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.
    Moorthy V; Reed Z; Smith PG;
    Vaccine; 2007 Jul; 25(28):5115-23. PubMed ID: 17577487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.
    Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA
    PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.
    Penny MA; Galactionova K; Tarantino M; Tanner M; Smith TA
    BMC Med; 2015 Jul; 13():170. PubMed ID: 26219380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.